Differential effects of imeglimin and metformin on insulin and incretin secretion—An exploratory randomized controlled trial
Unlike metformin, imeglimin enhances GIP secretion as well as GLP-1 secretion, in addition to its direct insulinotropic mechanism of glucose control, emphasizing its potential as a therapeutic option in the treatment of patients with diabetes.
Authors
- Y. Yamazaki (ORCID: https://orcid.org/0000-0003-3710-6995)
- Kenta Murotani (ORCID: https://orcid.org/0000-0003-0623-9365)
- Kazuhiro Shimomura (ORCID: https://orcid.org/0000-0002-9089-7485)
- Ryota Usui (ORCID: https://orcid.org/0000-0002-4641-0158)
- Yutaka Seino (ORCID: https://orcid.org/0000-0002-1099-7989)
- Yoshiyuki Hamamoto (ORCID: https://orcid.org/0000-0002-1938-7394)
- Hitoshi Kuwata (ORCID: https://orcid.org/0009-0000-5498-3282)
- Hisato Tatsuoka (ORCID: https://orcid.org/0000-0002-0669-6825)
- Yuichiro Yamada (ORCID: https://orcid.org/0000-0003-1623-0815)
- Yasuhiro Omori
- Masahiro Imura
Institutions
- Kurume University (JP)
- Kansai Electric Power (Japan) (JP)
- Kansai Electric Power Hospital (JP)
- Aichi Cancer Center (JP)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1111/dom.16086
- Citations
- 12
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 4.29